echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 80% of China's clinical data are not true is the "evidence" or "examination" of Innovent's rejection

    80% of China's clinical data are not true is the "evidence" or "examination" of Innovent's rejection

    • Last Update: 2022-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextClover

    On the evening of February 10, the FDA convened the Oncology Drug Advisory Committee ODAC to discuss and vote on the review of the new drug marketing application (BLA) for sintilimab injection


    Innovent’s sintilimab, as the “touchstone” of the single-country clinical data of a domestic innovative drug in the U.


    Uncover "Black History"

    Uncover "Black History"

    Is it true that 80% of Chinese clinical data are untrue?

    Is it true that 80% of Chinese clinical data are untrue?

    However, it is worth noting that when the review committee raised several controversial points about dilimumab, the FDA directly cited the report of the Chinese drug regulatory department, saying that 80% of Chinese clinical studies were fraudulent or substandard


    It is not difficult for careful readers to find that the report data cited by the FDA is the 2016 report of the China Food and Drug Administration


    Since then, China's new drug policy reform, chemical drug registration classification reform, BE filing system, recognition of foreign clinical trial data, and simultaneous development of international new drug clinical trials have been implemented.


    After years of policy combination and top-level design, China's drug research and development environment has been traced back to its roots, and China's new drug research and development has basically achieved international standards


    And the speed and data of China's drug research and development has been supported by many countries around the world


    FDA cites "7.


    FDA cites "7.


    "Proof" or "Pretext"?

    The ODAC's review of sintilimab, citing the data from the "7.


    The author believes that the FDA citing outdated data is actually unconvincing, or it is not a strong data supporting evidence that sintilimab is not approved by the FDA


    Looking back on the research and development process of sintilimab, according to Yaozhi's global marketed drug screening system, Innovent Bio first applied for the clinical trial of sintilimab in January 2016, and was approved for the trial license in early September 2016


    Data source: Yaozhi Data

    In addition, at this review meeting, the FDA actually recognized the clinical research data of sintilimab


    In fact, since the verification of clinical data on 7.


    Epilogue

    Epilogue

    However, we should face up to history and take this as a lesson to learn


    At the same time, I also hope that whether it is FDA, EMA or other national drug regulatory agencies, they will not turn out the "black history" every time they review the clinical data of Chinese drugs


    Look at problems from a developmental perspective
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.